Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of FDG-PET/CT with Rb-82 for Cardiac Sarcoidosis
NCT03048097Phase 1Completed
- Sponsor
- Yale University
- Start
- Feb 2017
- Primary completion
- Jul 2018
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Yale University. Primary endpoints: Visual interpretation of FDG uptake at 90 minutes, Severity of myocardial inflammation at 90 minutes and 1 more. Started Feb 2017; status: completed.
Beyond the preview
Go deeper on NCT03048097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03048097.